TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency

OBJECTIVE: Natalizumab blocks α4‐integrin‐mediated leukocyte migration into the central nervous system (CNS). It diminishes disease activity in multiple sclerosis (MS), but carries a high risk of progressive multifocal encephalopathy (PML), an opportunistic infection with JV virus that may be prompt...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Rehana Z., Cravens, Petra C., Doelger, Richard, Dentel, Brianne, Herndon, Emily, Loof, Nicolas, Tsai, Peter, Okuda, Darin T., Racke, Michael K., Stüve, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292184/
https://www.ncbi.nlm.nih.gov/pubmed/30564621
http://dx.doi.org/10.1002/acn3.664
_version_ 1783380368830758912
author Hussain, Rehana Z.
Cravens, Petra C.
Doelger, Richard
Dentel, Brianne
Herndon, Emily
Loof, Nicolas
Tsai, Peter
Okuda, Darin T.
Racke, Michael K.
Stüve, Olaf
author_facet Hussain, Rehana Z.
Cravens, Petra C.
Doelger, Richard
Dentel, Brianne
Herndon, Emily
Loof, Nicolas
Tsai, Peter
Okuda, Darin T.
Racke, Michael K.
Stüve, Olaf
author_sort Hussain, Rehana Z.
collection PubMed
description OBJECTIVE: Natalizumab blocks α4‐integrin‐mediated leukocyte migration into the central nervous system (CNS). It diminishes disease activity in multiple sclerosis (MS), but carries a high risk of progressive multifocal encephalopathy (PML), an opportunistic infection with JV virus that may be prompted by diminished CNS immune surveillance. The initial host response to viral infections entails the synthesis of type I interferons (IFN) upon engagement of TLR3 receptors. We hypothesized that TLR3 agonism reestablishes CNS immune competence in the setting of α4‐integrin deficiency. METHOD: We generated the conditional knock out mouse strain Mx1.Cre(+) α4‐integrin(fl/fl), in which the α4‐integrin gene is ablated upon treatment with the TLR3 agonist poly I:C. Adoptive transfer of purified lymphocytes from poly I:C‐treated Mx1.Cre(+) α4‐integrin(fl/fl) donors into naive recipients recapitulates immunosuppression under natalizumab. Active experimental autoimmune encephalomyelitis (EAE) in Mx1.Cre(+) α4‐integrin(fl/fl) mice treated with poly I:C represents immune‐reconstitution. RESULTS: Adoptive transfer of T cells from poly I:C treated Mx1.Cre(+) α4‐integrin(fl/fl) mice causes minimal EAE. The in vitro migratory capability of CD45(+) splenocytes from these mice is reduced. In contrast, actively‐induced EAE after poly I:C treatment results in full disease susceptibility of Mx1.Cre(+) α4‐integrin(fl/fl) mice, and the number and composition of CNS leukocytes is similar to controls. Extravasation of Evans Blue indicates a compromised blood‐brain barrier. Poly I:C treatment results in a 2‐fold increase in IFN β transcription in the spinal cord. INTERPRETATION: Our data suggest that TLR3 agonism in the setting of relative α4‐integrin deficiency can reestablish CNS immune surveillance in an experimental model. This pathway may present a feasible treatment strategy to treat and prevent PML under natalizumab therapy and should be considered for further experimental evaluation in a controlled setting.
format Online
Article
Text
id pubmed-6292184
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62921842018-12-18 TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency Hussain, Rehana Z. Cravens, Petra C. Doelger, Richard Dentel, Brianne Herndon, Emily Loof, Nicolas Tsai, Peter Okuda, Darin T. Racke, Michael K. Stüve, Olaf Ann Clin Transl Neurol Research Articles OBJECTIVE: Natalizumab blocks α4‐integrin‐mediated leukocyte migration into the central nervous system (CNS). It diminishes disease activity in multiple sclerosis (MS), but carries a high risk of progressive multifocal encephalopathy (PML), an opportunistic infection with JV virus that may be prompted by diminished CNS immune surveillance. The initial host response to viral infections entails the synthesis of type I interferons (IFN) upon engagement of TLR3 receptors. We hypothesized that TLR3 agonism reestablishes CNS immune competence in the setting of α4‐integrin deficiency. METHOD: We generated the conditional knock out mouse strain Mx1.Cre(+) α4‐integrin(fl/fl), in which the α4‐integrin gene is ablated upon treatment with the TLR3 agonist poly I:C. Adoptive transfer of purified lymphocytes from poly I:C‐treated Mx1.Cre(+) α4‐integrin(fl/fl) donors into naive recipients recapitulates immunosuppression under natalizumab. Active experimental autoimmune encephalomyelitis (EAE) in Mx1.Cre(+) α4‐integrin(fl/fl) mice treated with poly I:C represents immune‐reconstitution. RESULTS: Adoptive transfer of T cells from poly I:C treated Mx1.Cre(+) α4‐integrin(fl/fl) mice causes minimal EAE. The in vitro migratory capability of CD45(+) splenocytes from these mice is reduced. In contrast, actively‐induced EAE after poly I:C treatment results in full disease susceptibility of Mx1.Cre(+) α4‐integrin(fl/fl) mice, and the number and composition of CNS leukocytes is similar to controls. Extravasation of Evans Blue indicates a compromised blood‐brain barrier. Poly I:C treatment results in a 2‐fold increase in IFN β transcription in the spinal cord. INTERPRETATION: Our data suggest that TLR3 agonism in the setting of relative α4‐integrin deficiency can reestablish CNS immune surveillance in an experimental model. This pathway may present a feasible treatment strategy to treat and prevent PML under natalizumab therapy and should be considered for further experimental evaluation in a controlled setting. John Wiley and Sons Inc. 2018-10-30 /pmc/articles/PMC6292184/ /pubmed/30564621 http://dx.doi.org/10.1002/acn3.664 Text en © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Hussain, Rehana Z.
Cravens, Petra C.
Doelger, Richard
Dentel, Brianne
Herndon, Emily
Loof, Nicolas
Tsai, Peter
Okuda, Darin T.
Racke, Michael K.
Stüve, Olaf
TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency
title TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency
title_full TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency
title_fullStr TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency
title_full_unstemmed TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency
title_short TLR3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency
title_sort tlr3 agonism re‐establishes cns immune competence during α4‐integrin deficiency
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292184/
https://www.ncbi.nlm.nih.gov/pubmed/30564621
http://dx.doi.org/10.1002/acn3.664
work_keys_str_mv AT hussainrehanaz tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency
AT cravenspetrac tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency
AT doelgerrichard tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency
AT dentelbrianne tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency
AT herndonemily tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency
AT loofnicolas tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency
AT tsaipeter tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency
AT okudadarint tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency
AT rackemichaelk tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency
AT stuveolaf tlr3agonismreestablishescnsimmunecompetenceduringa4integrindeficiency